BANZEL

LOE Approaching

rufinamide

NDAORALSUSPENSION
Approved
Mar 2011
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
5

Mechanism of Action

mechanism(s) by which rufinamide exerts its antiepileptic effect is unknown. The results of in vitro studies suggest that the principal mechanism of action of rufinamide is modulation of the activity of sodium channels and, in particular, prolongation of the inactive state of the channel.…

Clinical Trials (5)

NCT06740825Phase 1Completed

Study to Assess the Effect of a CYP3A Weak Inducer Rufinamide on Quizartinib Pharmacokinetics in Healthy Subjects

Started Oct 2024
32 enrolled
Healthy Subjects
NCT01405053Phase 3Completed

Study of Rufinamide in Pediatric Subjects 1 to Less Than 4 Years of Age With Lennox-Gastaut Syndrome Inadequately Controlled With Other Anti-epileptic Drugs

Started Jun 2011
37 enrolled
Lennox-Gastaut Syndrome
NCT00448539Phase 3Terminated

Open-Label Extension Study of Rufinamide Given as Adjunctive Therapy in Patients With Refractory Partial Seizures

Started Mar 2007
286 enrolled
Refractory Partial Onset Seizures
NCT00334958Phase 3Completed

Rufinamide Given as Adjunctive Therapy in Participants With Refractory Partial Seizures

Started Feb 2006
356 enrolled
Epilepsy
NCT03778424N/AAvailable

An Extended Access Program (EAP) for Participants Who Have Completed Rufinamide Study E2080-G000-303

Lennox Gastaut Syndrome